https://www.selleckchem.com/pr....oducts/halofuginone.
0%) had a significantly lower probability of disease-free rates as compared to TNBC patients who are carriers of CYP1B1 4326 CC/CG genotypes (71.0%). Univariate and multivariate Cox analysis demonstrated that TNBC patients who carried CYP1B1 4326 GG variant genotype had a significantly higher risk of recurrence with HR 2.50 and HR 4.18 respectively, even after adjustment as compared to TNBC patients who were carriers of CYP1B1 4326 CC and CG genotypes. Our results demonstrate the potential use of CYP1B1 4325 GG variant genotype as
Like
Comment
Share
